AZD4635, a novel oral adenosine A2A receptor antagonist, shows clinical activity as a monotherapy or in combination with Imfinzi® (durvalumab) in patients with advanced solid tumors (AACR 2019)
By AstraZeneca | Apr 14, 2019
AACR Annual Meeting 2019
29 March – 3 April 2019
American Association for Cancer Research
AstraZeneca presented new clinical data from its Phase 1a study with AZD4635, a next-generation immuno-oncology candidate, as a single agent and in combination with the PD-L1 antibody durvalumab, in patients with advanced solid tumors, at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, USA (29 March to 3 April 2019).
AZD4635 is a potent and selective, orally available, small molecule adenosine 2A receptor (A2AR) antagonist discovered by Sosei Heptares and exclusively licensed to AstraZeneca in 2015. Adenosine signalling is a normal process preventing autoimmunity that is co-opted by tumors as an immune escape mechanism. The adenosine pathway is increasingly recognized as critical to tumor suppression and represents a new frontier within immuno-oncology.
The poster (abstract #CT026) was entitled “Evidence of immune activation in the first-in-human Phase 1a dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors,” and reported the following: